Published in Healthcare Mergers, Acquisitions and Ventures Week, May 5th, 2007
The Phase III trial is being conducted initially in 40 hospitals across Australia, the UK and Ireland, and is the final clinical step before Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the European Union, Australia and elsewhere.
Pharmaxis Chief Executive Officer Dr Alan Robertson said: "It's great news to get this trial underway and it represents significant progress for our cystic fibrosis programme. For the first time, we are offering...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week